Barbara C. Kahl

Prof. Barbara C. Kahl

Institute of Medical Microbiology, University Hospital of Münster, 48149 Münster, Germany
orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2006 in Nature Reviews Microbiology
Verified
Journal Article
Closed access
RPRichard A. Proctor
Richard A. Proctor
CEChristof von Eiff
Christof von Eiff
BKBarbara C. Kahl
Barbara C. Kahl
Karsten BeckerKarsten Becker
Karsten Becker
PMPeter McNamara
Peter McNamara
GPGeorg Peters
Georg Peters

31 December 2013 in mBio
Verified
Journal Article
Open access
PDF file
LPLance B Price
Lance B Price
JJJames R Johnson
James R Johnson
MAMaliha Aziz
Maliha Aziz
CCConnie Clabots
Connie Clabots
BJBrian Johnston
Brian Johnston
ESEvgeni V Sokurenko
Evgeni V Sokurenko
The Escherichia coli sequence type 131 (ST131) clone is notorious for extraintestinal infections, fluoroquinolone resistance, and extended-spectrum beta-lactamase (ESBL) production, attributable to a CTX-M-15-encoding mobile element. Here, we applied pulsed-field gel electrophoresis (PFGE) and whole-genome sequencing to reconstruct the evolutionary history of the ST131 clone. PFGE-based cluster analyses suggested that both fluoroquinolone resistance and ESBL production had been acquired by multiple ST131 sublineages through independent genetic events. In contrast, the more robust whole-genome-sequence-based phylogenomic analysis revealed that fluoroquinolone resistance was confined almost entirely to a single, rapidly expanding ST131 subclone, designated H 30-R. Strikingly, 91% of the CTX-M-15-producing isolates also belonged to a single, well-defined clade nested within H 30-R, which was named H 30-Rx due to its more extensive resistance. Despite its tight clonal relationship with H 30Rx, the CTX-M-15 mobile element was inserted variably in plasmid and chromosomal locations within the H 30-Rx genome. Screening of a large collection of recent clinical E. coli isolates both confirmed the global clonal expansion of H 30-Rx and revealed its disproportionate association with sepsis (relative risk, 7.5; P < 0.001). Together, these results suggest that the high prevalence of CTX-M-15 production among ST131 isolates is due primarily to the expansion of a single, highly virulent subclone, H 30-Rx. IMPORTANCE We applied an advanced genomic approach to study the recent evolutionary history of one of the most important Escherichia coli strains in circulation today. This strain, called sequence type 131 (ST131), causes multidrug-resistant bladder, kidney, and bloodstream infections around the world. The rising prevalence of antibiotic resistance in E. coli is making these infections more difficult to treat and is leading to increased mortality. Past studies suggested that many different ST131 strains gained resistance to extended-spectrum cephalosporins independently. In contrast, our research indicates that most extended-spectrum-cephalosporin-resistant ST131 strains belong to a single highly pathogenic subclone, called H 30-Rx. The clonal nature of H 30-Rx may provide opportunities for vaccine or transmission prevention-based control strategies, which could gain importance as H 30-Rx and other extraintestinal pathogenic E. coli subclones become resistant to our best antibiotics.

8 January 2010 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
BLBettina Löffler
Bettina Löffler
MHMuzaffar Hussain
Muzaffar Hussain
MGMatthias Grundmeier
Matthias Grundmeier
MBMichaela Brück
Michaela Brück
DHDirk Holzinger
Dirk Holzinger
GPGeorg Peters
Georg Peters
The role of the pore-forming Staphylococcus aureus toxin Panton-Valentine leukocidin (PVL) in severe necrotizing diseases is debated due to conflicting data from epidemiological studies of community-associated methicillin-resistant S. aureus (CA-MRSA) infections and various murine disease-models. In this study, we used neutrophils isolated from different species to evaluate the cytotoxic effect of PVL in comparison to other staphylococcal cytolytic components. Furthermore, to study the impact of PVL we expressed it heterologously in a non-virulent staphylococcal species and examined pvl-positive and pvl-negative clinical isolates as well as the strain USA300 and its pvl-negative mutant. We demonstrate that PVL induces rapid activation and cell death in human and rabbit neutrophils, but not in murine or simian cells. By contrast, the phenol-soluble modulins (PSMs), a newly identified group of cytolytic staphylococcal components, lack species-specificity. In general, after phagocytosis of bacteria different pvl-positive and pvl-negative staphylococcal strains, expressing a variety of other virulence factors (such as surface proteins), induced cell death in neutrophils, which is most likely associated with the physiological clearing function of these cells. However, the release of PVL by staphylococcal strains caused rapid and premature cell death, which is different from the physiological (and programmed) cell death of neutrophils following phagocytosis and degradation of virulent bacteria. Taken together, our results question the value of infection-models in mice and non-human primates to elucidate the impact of PVL. Our data clearly demonstrate that PVL acts differentially on neutrophils of various species and suggests that PVL has an important cytotoxic role in human neutrophils, which has major implications for the pathogenesis of CA-MRSA infections. Staphylococcus aureus can cause serious diseases, including necrotizing pneumonia, which often affects young immunocompetent patients and has a high lethality rate. Several clinical studies demonstrated a clear association between this form of pneumonia and S. aureus strains carrying the gene for the pore-forming toxin Panton-Valentine leukocidin (PVL). However, laboratory work, which mainly used murine disease models, has created very contrasting results and often fails to show a pathogenic role for PVL. In this study, we demonstrate that the expression of PVL by staphylococcal strains confers strong and rapid cytotoxic activity against neutrophils. However, this action was basically restricted to human cells and could not be reproduced in murine or Java monkeys’ cells. These results indicate that infection-models in mice and in non-human primates fail to replicate the pathogenic activity of PVL seen in human cells. Our data with human neutrophils clearly show that PVL has a major cytotoxic effect, as the release of PVL by staphylococcal strains caused rapid and premature cell death, which is different from the physiological (and programmed) cell death of neutrophils following phagocytosis and degradation of virulent bacteria. These results have important implications especially for infections with CA-MRSA strains, which often carry the gene for PVL and have spread widely in the community.

1 April 2016 in Clinical Microbiology Reviews
Verified
Journal Article
Closed access
PDF file
BKBarbara C. Kahl
Barbara C. Kahl
Karsten BeckerKarsten Becker
Karsten Becker
BLBettina Löffler
Bettina Löffler
SUMMARY Small colony variants (SCVs) were first described more than 100 years ago for Staphylococcus aureus and various coagulase-negative staphylococci. Two decades ago, an association between chronic staphylococcal infections and the presence of SCVs was observed. Since then, many clinical studies and observations have been published which tie recurrent, persistent staphylococcal infections, including device-associated infections, bone and tissue infections, and airway infections of cystic fibrosis patients, to this special phenotype. By their intracellular lifestyle, SCVs exhibit so-called phenotypic (or functional) resistance beyond the classical resistance mechanisms, and they can often be retrieved from therapy-refractory courses of infection. In this review, the various clinical infections where SCVs can be expected and isolated, diagnostic procedures for optimized species confirmation, and the pathogenesis of SCVs, including defined underlying molecular mechanisms and the phenotype switch phenomenon, are presented. Moreover, relevant animal models and suggested treatment regimens, as well as the requirements for future research areas, are highlighted.

1 April 1998 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
BKBarbara C. Kahl
Barbara C. Kahl
MHMathias Herrmann
Mathias Herrmann
AEAnne Schulze Everding
Anne Schulze Everding
HKHans G. Koch
Hans G. Koch
Karsten BeckerKarsten Becker
Karsten Becker
GPGeorg Peters
Georg Peters
In a 34-month prospective study to determine the prevalence of Staphylococcus aureus small colony variants (SCVs) in cystic fibrosis (CF) patients, S

28 July 2014 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
PDF file
RPRichard A. Proctor
Richard A. Proctor
AKAndrã© Kriegeskorte
Andrã© Kriegeskorte
BKBarbara C. Kahl
Barbara C. Kahl
Karsten BeckerKarsten Becker
Karsten Becker
BLBettina Lã¶Ffler
Bettina Lã¶Ffler
GPGeorg Peters
Georg Peters
Persistent and relapsing infections, despite apparently adequate antibiotic therapy, occur frequently with many pathogens, but it is an especially prominent problem with Staphylococcus aureus infections. For the purposes of this review, persistence will encompass both of the concepts of long term survival within the host, including colonization, and the concept of resisting antibiotic therapy even when susceptible in the clinical microbiology laboratory. Over the past two decades, the mechanisms whereby bacteria achieve persistence are slowly being unraveled. S. aureus small colony variants (SCVs) are linked to chronic, recurrent, and antibiotic-resistant infections, and the study of SCVs has contributed significantly to understanding of persistence. In our earlier work, defects in electron transport and thymidylate biosynthesis were linked to the development of the SCV phenotype (reviewed in 2006), thus this work will be discussed only briefly. Since 2006, it has been found that persistent organisms including SCVs are part of the normal life cycle of bacteria, and often they arise in response to harsh conditions, e.g., antibiotics, starvation, host cationic peptides. Many of the changes found in these early SCVs have provided a map for the discovery mechanisms (pathways) for the development of persistent organisms. For example, changes in RNA processing, stringent response, toxin-antitoxin, ribosome protein L6 (RplF), and cold shock protein B (CspB) found in SCVs are also found in other persisters. In addition, many classic persister organisms also show slow growth, hence SCVs. Recent work on S. aureus USA300 has elucidated the impact of aerobic expression of arginine deiminase genes on its ability to chronically colonize the skin and survive in abscesses. S. aureus SCVs also express arginine deiminase genes aerobically as well. Thus, many pathways found activated in electron transport type of SCVs are also increased in persisters that have intact electr